Skin lightening preparations and the hydroquinone controversy

Dermatologic Therapy

Volumn 20, Issue 5, 2007, Pages 308-313

  Draelos, Zoe Diana ^a,b,c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DERMATOLOGY CONSULTING SERVICES   (United States)

^c NONE   (United States)

Author keywords

Hydroquinone safety; Pigment lightening; Topical skin lightening cosmeceuticals

Indexed keywords

ALEOSIN; ALOIN; ARBUTIN; ASCORBIC ACID; ASCORBYL PALMITATE; AZELAIC ACID; CORTICOSTEROID; GLYCYRRHIZA EXTRACT; HYDROQUINONE; KOJIC ACID; MEQUINOL; N ACETYLGLUCOSAMINE; RETINOIC ACID; RETINOID; SOYBEAN PROTEIN; SOYBEAN TRYPSIN INHIBITOR; TAZAROTENE; UNCLASSIFIED DRUG;

ACNE; CHLOASMA; DERMATITIS; DERMATOLOGY; DRUG APPROVAL; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRY SKIN; DYSCHROMIA; ERYTHEMA; EUROPE; EYE; GOLD STANDARD; HUMAN; HYPERPIGMENTATION; JAPAN; LENTIGO; REVIEW; ROSACEA; SKIN CARE; SKIN DEFECT; SKIN INJURY; SKIN IRRITATION; SKIN LIGHTENING; SKIN PIGMENTATION; SKIN SCALING; UNITED STATES;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTHETICS; FEMALE; HUMANS; HYDROQUINONES; HYPERPIGMENTATION; MALE; MELANOSIS; PATIENT SATISFACTION; RETINOIDS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SKIN CARE; TREATMENT OUTCOME;

EID: 36649036991     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2007.00144.x     Document Type: Review

References (28)

1. Kligman LH, Gans EH. Re-emergence of topical retinol in dermatology. J Dermatol Treatment 2000 : 11 : 47 52.
2. Draelos ZD. Hydroquinone: optimizing therapeutic outcomes in the clinical setting of melanin-related hyperpigmentation. J New Dev Clin Med 2001 : 19 : 191 201.
3. Lawrence N, Bligard CA, Reed R, et al. Exogenous ochronosis in the United States. J Am Acad Dermatol 1988 : 18 : 1207 1211.
4. Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Euro Acad Dermatol Venerol 2006 : 781 787.
5. Halder RM, Richards GM. Management of dischromias in ethnic skin. Dermatol Ther 2004 : 17 : 151 157.
6. Kligman AM, Grove GL, Hirose R, Leyden JJ. Topical tretinoin for photoaged skin. J Am Acad Dermatol 1986 : 15 : 836 859.
7. Kligman AM. The treatment of photoaged human skin by topical tretinoin. Drugs 1989 : 38 : 1 8.
8. Weinstein GD, Nigra TP, Pochi PE, et al. Topical tretinoin for treatment of photodamaged skin. Arch Dermatol 1991 : 127 : 659 665.
9. Gilchrest BA, Blog FB, Szabo G. Effects of aging and chronic sun exposure on melanocytes in human skin. J Invest Dermatol 1979 : 73 : 141 143.
10. Bhawan J, Serva AG, Nehal K, et al. Effects of tretinoin on photodamaged skin a histologic study. Arch Dermatol 1991 : 127 : 666 672.
11. Kang S, Duell EA, Voorhees JJ, et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels of irritation. J Invest Dermatol 1995 : 105 : 549 556.
12. Duell EA, Kang S, Voorhees JJ. Unoccluded retinol penetrates human skin in vivo more effectively than unoccluded retinyl palmitate or retinoic acid. J Invest Dermatol 1997 : 109 : 301 305.
13. Green CK, Griffiths CEM, Finkel LJ, et al. Topical retinoic acid (tretinoin) for melasma in Black patients. Arch Dermatol 1994 : 130 : 727 733.
14. Fitton A, Goa KL. Azelaic acid: a review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. Drugs 1991 : 5 : 780 798.
15. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991 : 30 : 893 895.
16. Hori I, Nihei K, Kubo I. Structural criteria for depigmenting mechanism of arbutin. Phytother Res 2004 : 18 : 475 469.
17. Oissy RE, Visscher M, DeLong MA. Deoxyarbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol 2005 : 14 : 601.
18. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 1999 : 25 : 282 284.
19. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1996 : 22 : 443 447.
20. Choi S, Lee SK, Kim JE, et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol 2002 : 27 : 513 515.
21. Jones K, Hughes J, Hong M, et al. Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Res 2002 : 15 : 335 340.
22. Amer M, Metwalli M. Topical Liquiritin improves melasma. Int J Dermatol 2000 : 39 : 299 301.
23. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double blind randomized trial of 5% ascorbic acid vs 4% hydroquinone in melasma. Int J Dermatol 2004 : 43 : 604 607.
24. Seiberg M, Paine C, Sharlow E, et al. Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol 2000 : 115 : 162 167.
25. Paine C, Sharlow E, Liebel F, et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol 2001 : 116 : 587 595.
26. Bissett DL. Glucosamine: an ingredient with skin and other benefits. J Cosmet Dermatol 2006 : 5 : 309 315.
27. Bissett DL, McPhail SJ, Farmer TL, et al. Topical N-acetyl glucosamine affects pigmentation-relevant genes in in vitro genomics testing. Pig Cell Res 2006 : 19 : 373.
28. Bissett DL, Robinson L, Li J, Miyamoto K. Topical N-acetyl glucosamine reduces the appearance of hyperpigmented spots on human facial skin. J Am Acad Dermatol 2006 : 54 : AB54.